Tumor-infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34352937/
doi: 10.4048/jbc.2021.24.e36. Online ahead of print. 1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 2 Division of Hemato-Oncology, Department of Internal Medicine, Chung-Ang...
Predicting chronic pain in postoperative breast cancer patients with multiple machine learning and deep learning models - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34364190/
doi: 10.1016/j.jclinane.2021.110423. Online ahead of print. 1 Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China. 2 Department of Anesthesiology, Pain and...
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34324367/
Alpelisib in combination with endocrine therapy (ET) should be offered to postmenopausal patients, and to male patients, with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA -mutated, ABC, or...
In vitro therapeutic effects of abemaciclib on triple-negative breast cancer cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34309953/
The cyclin-dependent kinases 4 and 6 have led to a significant improvement in the treatment of hormone-receptor-positive breast cancer. However, the therapeutic potential of abemaciclib in triple-negative breast cancer (TNBC)...
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34327137/
Targeted therapies such as Cyclin Dependent Kinase 4 and 6 (CDK 4/6) inhibitors have improved the prognosis of metastatic hormone receptor (HR) positive breast cancer by combating the resistance seen...